It’s clear from Teva’s CC today that no contribution from Lovenox is in Teva’s 2011 guidance. (Nor, for that matter, has any contribution from Lovenox ever been in Teva’s prior guidance—see #msg-58308206.)
Please see #msg-56956538 for Teva’s sales and EPS guidance for 2015, which is unchanged.
*Non-GAAP.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.